Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

9MW 2821

Next Previous
X
Search
Drug Profile

9MW 2821

Alternative Names: 9MW-2821

Latest Information Update: 22 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabwell (Shanghai) Bioscience
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Urogenital cancer
  • Phase I/II Solid tumours
  • Phase I Bladder cancer

Most Recent Events

  • 13 Nov 2024 CDE of NMPA approved IND application for two clinical studies
  • 13 Nov 2024 Mabwell plans clinical trial Urothelial carcinoma and Solid tumours (Combination therapy, Late-stage diseases)
  • 25 Aug 2024 Phase-III clinical trials in Urogenital cancer (First-line therapy, Metastatic disease, Late-stage disease, Combination therapy) (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top